Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease
This article was originally published in Scrip
Gilead Sciences Inc. knows a thing or two about developing successful liver disease therapies, since it owns the world's top two hepatitis C drugs in terms of sales, and now the company is attempting to dominate another liver disease with the purchase of Nimbus Apollo Inc. for up to $1.2bn.
You may also be interested in...
Takeda’s R&D chief Andy Plump said his company has seen data indicating game-changing characteristics for TAK-279 in psoriasis. It plans to bring the candidate into Phase III next year.
Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.
Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.